Navigation Links
Anthera Presents Data on Varespladib at ATVB Meeting
Date:4/17/2008

SAN MATEO, Calif., April 17 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that Anthera scientists and collaborators have released data from the Varespladib (A-002) clinical and pre-clinical programs at the Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Annual Conference in Atlanta, Georgia, held on April 16-18, 2008. Anthera has completed Phase II trials in Varespladib for the treatment of coronary heart disease.
Posters include:

-- Effects of a Selective Secretory Phospholipase A2 Inhibitor on

Low-Density Lipoproteins in CHD Patients with Diabetes.

-- The Synergistic Inhibition of Atherogenesis in ApoE-/- Mice Between

Pravastatin and the sPLA2 Inhibitor Varespladib (A-002).

"We are pleased to see the synergistic effect of Varespladib with statins on plaque reduction, composition and stability in a well established model of atherosclerosis," said Joaquim Trias, Ph.D., Senior Vice President of Preclinical Development at Anthera Pharmaceuticals, Inc.

"Along with the Phase II PLASMA data presented at ACC earlier this year, today's announcement gives us added confidence as we move the Varespladib clinical program forward," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "These findings further support our clinical development program as we begin Phase III clinical trials in patients with acute coronary syndromes where inflammation, atherosclerosis and cholesterol levels are highly correlated with outcomes."

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shion
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Anthera Pharmaceuticals Forms Scientific Advisory Board
2. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
3. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
4. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
5. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
6. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
7. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
8. SGX Presents Preclinical MET Data at AACR
9. ARIUS presents new findings for anti-cancer antibody programs at AACR
10. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
11. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 Repligen Corporation (Nasdaq: ... received $731,000 in research funding to support the ... from the Muscular Dystrophy Association (MDA). This ... toxicology testing and GMP manufacture of a drug ... the MDA not only provides important funding for ...
(Date:12/15/2009)... Atomic Force Microscopy (AFM) have been developed and are opening ... liquid/air interface. The NeedleProbes’ cylindrical geometry enables researchers to ... viscosity - all in a single force distance curve. ... ... New, constant diameter NeedleProbes are enabling unique measurements ...
(Date:12/15/2009)... LONDON, Dec. 15 Thomson ... Pharma ® has become the first drug pipeline ... and outcome information. This highly anticipated new content ... this month. ,, Thomson Pharma ... from registries, publications, press releases, conferences, and other ...
(Date:12/14/2009)... Dyadic International, Inc. (Pink Sheets: DYAI) ... collaboration with The Scripps Research Institute ("Scripps") by ... the genome of Dyadic,s patented and proprietary C1 ... of the successful relationship between the two organizations ... Scripps to annotate the C1 genome for the ...
Breaking Biology Technology:Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 2New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 3Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5
... Mass., Jan. 13 Verenium Corporation,(Nasdaq: ... development of next-generation cellulosic,ethanol and high-performance specialty ... with the continued listing requirements of The ... it had fallen out of,compliance with NASDAQ ...
... Presentation Scheduled for Thursday, January 15th at 1:00PM PTNEW ... KERX ) today announced that Michael S. Weiss, ... to present at the J.P. Morgan 27th Annual Healthcare ... be webcast live on Thursday, January 15th at 1:00pm ...
... JOLLA, Calif., Jan. 13 Burnham Institute ... assay development and license agreement with Johnson ... (J&JPRD). The agreement is Burnham,s first ... this multi-year agreement, Burnham will provide J&JPRD ...
Other Biology Technology:Verenium Regains Compliance With Nasdaq Continued Listing Requirement 2Verenium Regains Compliance With Nasdaq Continued Listing Requirement 3Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2
(Date:12/15/2009)... British Society for Research on Ageing (BSRA) to enter ... for an initial period of three years. The ... editorial board and will acquire articles for one ... and provide society members with free electronic access to ... Biogerontology offers a platform for research which aims ...
(Date:12/15/2009)... ., Despite the fact that physical space follows ... to how space is encoded in their language. Some, ... ,left, right, front, back, to talk about spatial relations, ... at all times for all scales: "The spoon is ... by your Northern leg". Whether not only spatial language ...
(Date:12/15/2009)... The mouse is a standard laboratory model organism, ... conventional techniques to analyze blood and blood-forming tissues ... of compact and easy-to-use laboratory resources from Cold ... Mouse Hematology features step-by-step protocols for ... blood, bone marrow, and other hematopoietic tissues in ...
Breaking Biology News(10 mins):More than a jump to the left 2New source of classical techniques for blood-based studies in the laboratory mouse 2Macomb County Announces New Location for Four Upcoming H1N1 Clinics 63074 1Macomb County Announces New Location for Four Upcoming H1N1 Clinics 63074 2American Association of Poison Control Centers 3A Treat Poinsettias and Mistletoe with Respect Rather Than Fear This Holiday Season 63071 1American Association of Poison Control Centers 3A Treat Poinsettias and Mistletoe with Respect Rather Than Fear This Holiday Season 63071 2California Breast Cancer Survivors and Advocates Call on State to Nix Screening Cuts 63066 1California Breast Cancer Survivors and Advocates Call on State to Nix Screening Cuts 63066 2California Breast Cancer Survivors and Advocates Call on State to Nix Screening Cuts 63066 3
... today announced that it has for the first time ... for all of its microarrays. The release of this ... cross-platform data comparison. , "Full release of the probe ... to take," said Catherine Ball, president of the Microarray ...
... mussels and oysters are important vehicles for the ... undercooked. Vibrio species, including human pathogens, are particularly ... even after cleaning procedures, thus representing a potential ... are well known to affect the persistence of ...
... physical support and taking in nutrients, plant roots ... other nearby roots, as well as insects and ... root activity has not been extensively investigated—until now. ... of garden-variety cabbage, Jorge Vivanco and co-workers at ...
Other Biology News:Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays 2Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host. 2Roots Engage in Underground Chemical Warfare 2
albumin from bovine serum (BSA), Alexa Fluor® 647 conjugate...
albumin from bovine serum (BSA), BODIPY® FL conjugate...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
... (human, bovine, porcine, rat) ... receptor antagonist. This carboxy-terminal VIP ... twofold more potent than any ... Storage: ...
Biology Products: